Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response.

Miller C, Guillaume D, Dusenbery K, Clark HB, Moertel C.

J Neurosurg Pediatr. 2017 Mar;19(3):319-324. doi: 10.3171/2016.9.PEDS16328. Epub 2016 Dec 23.

PMID:
28009226
2.

Pilocytic astrocytomas of the optic nerve and their relation to pilocytic astrocytomas elsewhere in the central nervous system.

Reis GF, Bloomer MM, Perry A, Phillips JJ, Grenert JP, Karnezis AN, Tihan T.

Mod Pathol. 2013 Oct;26(10):1279-87. doi: 10.1038/modpathol.2013.79. Epub 2013 May 24.

3.

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.

Drobysheva A, Klesse LJ, Bowers DC, Rajaram V, Rakheja D, Timmons CF, Wang J, Koral K, Gargan L, Ramos E, Park JY.

J Natl Compr Canc Netw. 2017 Aug;15(8):978-982. doi: 10.6004/jnccn.2017.0139.

PMID:
28784858
4.

Role of surgery for optic pathway/hypothalamic astrocytomas in children.

Sawamura Y, Kamada K, Kamoshima Y, Yamaguchi S, Tajima T, Tsubaki J, Fujimaki T.

Neuro Oncol. 2008 Oct;10(5):725-33. doi: 10.1215/15228517-2008-033. Epub 2008 Jul 8.

5.

Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.

Chung C, Reilly S.

Am J Health Syst Pharm. 2015 Jan 15;72(2):101-10. doi: 10.2146/ajhp140045. Review.

PMID:
25550132
6.

The role of surgery in optic pathway/hypothalamic gliomas in children.

Goodden J, Pizer B, Pettorini B, Williams D, Blair J, Didi M, Thorp N, Mallucci C.

J Neurosurg Pediatr. 2014 Jan;13(1):1-12. doi: 10.3171/2013.8.PEDS12546. Epub 2013 Oct 18.

PMID:
24138145
7.

Chemotherapy with cisplatin and vincristine for optic pathway/hypothalamic astrocytoma in young children.

Sawamura Y, Kamoshima Y, Kato T, Tajima T, Tsubaki J.

Jpn J Clin Oncol. 2009 May;39(5):277-83. doi: 10.1093/jjco/hyp012. Epub 2009 Feb 17.

PMID:
19224939
8.

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.

Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, Yelensky R, Lipson D, Ali SM, Elvin JA, Vergilio JA, Roels S, Miller VA, Nakamura BN, Gray A, Wong MK, Stephens PJ.

Int J Cancer. 2016 Feb 15;138(4):881-90. doi: 10.1002/ijc.29825. Epub 2015 Sep 8.

9.

Trametinib (GSK1120212) in the treatment of melanoma.

Salama AK, Kim KB.

Expert Opin Pharmacother. 2013 Apr;14(5):619-27. doi: 10.1517/14656566.2013.770475. Epub 2013 Feb 23. Review.

PMID:
23432625
11.
12.

Pilocytic astrocytoma: a disease with evolving molecular heterogeneity.

Sadighi Z, Slopis J.

J Child Neurol. 2013 May;28(5):625-32. doi: 10.1177/0883073813476141. Epub 2013 Feb 25. Review.

PMID:
23439714
13.

Trametinib in the treatment of melanoma.

Thota R, Johnson DB, Sosman JA.

Expert Opin Biol Ther. 2015 May;15(5):735-47. doi: 10.1517/14712598.2015.1026323. Epub 2015 Mar 26. Review.

PMID:
25812921
14.

Diencephalic syndrome: a frequently delayed diagnosis in failure to thrive.

Huber J, Sovinz P, Lackner H, Mokry M, Eder H, Urban C.

Klin Padiatr. 2007 Mar-Apr;219(2):91-4.

PMID:
17405074
15.

Molecular characterization of disseminated pilocytic astrocytomas.

Gessi M, Engels AC, Lambert S, Rothämel T, von Hornstein S, Collins VP, Denkhaus D, Gnekow A, Pietsch T.

Neuropathol Appl Neurobiol. 2016 Apr;42(3):273-8. doi: 10.1111/nan.12256. Epub 2015 Jul 20.

PMID:
26084390
16.

Cisplatin/vincristine chemotherapy for hypothalamic/visual pathway astrocytomas in young children.

Kato T, Sawamura Y, Tada M, Ikeda J, Ishii N, Abe H.

J Neurooncol. 1998 May;37(3):263-70.

PMID:
9524084
17.

Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy.

Petronio J, Edwards MS, Prados M, Freyberger S, Rabbitt J, Silver P, Levin VA.

J Neurosurg. 1991 May;74(5):701-8.

PMID:
1901597
18.

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

Tolcher AW, Patnaik A, Papadopoulos KP, Rasco DW, Becerra CR, Allred AJ, Orford K, Aktan G, Ferron-Brady G, Ibrahim N, Gauvin J, Motwani M, Cornfeld M.

Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9. doi: 10.1007/s00280-014-2615-5. Epub 2014 Nov 25.

PMID:
25417902
19.

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, Goldberg JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DT, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, Allen JC.

Neuro Oncol. 2014 Oct;16(10):1408-16. doi: 10.1093/neuonc/nou059. Epub 2014 May 6.

20.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group.

N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.

Supplemental Content

Support Center